Section 22-B1328. THERAPEUTIC INTERCHANGE

 

1328.1 This section shall not apply to generic drug substitutions.  For generic drug substitutions, see the requirements of § 1326 of this chapter.

 

1328.2.1 As used in this section, “therapeutic interchange” means the dispensing of chemically different drugs that are considered to be therapeutically equivalent.

 

1328.3 A therapeutic interchange shall not be made without the prior approval of the prescribing practitioner. 

 

1328.4The approval required pursuant to § 1328.3 may be in the form of a readily retrievable, written, documented policy maintained by the pharmacy which clearly indicates that the provider has intended to approve the therapeutic interchange. 

 

1328.5  The patient shall be notified of the therapeutic interchange prior to, or upon delivery, of the dispensed prescription to the patient.  The notification shall include:

 

(a) A description of the change;

 

(b) The reason for the change; and

 

(c) Contact information indicating who the patient may contact with questions concerning the change.

 

 

authority

Section 19(a)(3) of the District of Columbia Pharmacist and Pharmacy Regulation Act of 1980, effective September 16, 1980, (D.C. Law 3-98; D.C. Official Code § 47-2885.18.01(a)(3)); the District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D. C. Law 4-29; D.C. Official Code § 48-901.01); Mayor’s Order 98-48, dated April 15, 1998, Section 4902 of the Fiscal Year 2002 Budget Support Act of 2001, effective October 3, 2001 (D.C. Law 14-28; D.C. Official Code § 7-731); Section 15 of the District of Columbia Drug Manufacture and Distribution Licensure Act of 1990, effective June 13, 1990 (D.C. Law 8-137; D.C. Official Code § 48-714(a)); and Mayor’s Order 98-88, dated May 29, 1998.

source

Final Rulemaking published at 56 DCR 4742 (June 19, 2009).